With this ground-breaking invention, the Vericheck ddPCR Empty-Full Capsid Kit streamlines the AAV development to produce dependable results. Using ddPCR technology, obtaining absolute ...

Roche has exercised its option to license a novel capsid from Dyno Therapeutics for use in a gene therapy program for an ...

The biotech is developing a Huntington’s disease (HD) gene therapy based on its proprietary capsid, AAV-DB-3. HD damages the neurons in the striatum, leading Latus to target the deep brain.

Improved AAV tropism is essential for gene therapy to reach its full potential. New capsid engineering techniques are taking on this challenge. Clinical translation of gene therapies has a history ...

In this talk, David Apiyo, Manager of Application Development at Sartorius (Göttingen, Germany), proposes a method that extends the use of AAVX biosensors to determine empty-to-full capsid ratios.

AAV9 is known to have some natural ability to penetrate the blood-brain barrier, and researchers have generated AAV9 capsid variants that efficiently cross the blood-brain barrier and enter neurons in ...

Astellas Pharma and Sangamo Therapeutics have signed a licence agreement for a neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, aimed at treating neurological diseases. Astellas will ...

One capsid, AAV-KP1, stood out as particularly effective when administered directly to the kidneys via the renal vein or pelvis, reaching kidney cells with minimal impact on the liver. In contrast ...

Two fundamental aspects of AAV research are the accurate quantification of AAV capsid titters and the detection of pre-existing antibodies against AAV. These measurements are essential for ensuring ...

The capsid license follows an agreement between Dyno and Roche originally announced in May 2020 and marks Dyno’s first adeno-associated virus (AAV) capsid licensing and partnership completion.